Form 4: BMY CFO David Elkins Executes Planned Stock Sale
Statement of Changes in Beneficial Ownership
Bristol-Myers Squibb CFO David V. Elkins sold 30,000 shares of common stock pursuant to a pre-established Rule 10b5-1 trading plan.
Summary
- David V. Elkins, EVP and Chief Financial Officer of Bristol-Myers Squibb, sold a total of 30,000 shares of common stock on April 1, 2026.
- The sales were executed in two tranches: 25,519 shares at a weighted average price of $61.60 and 4,481 shares at a weighted average price of $62.05.
- Following these transactions, the reporting person maintains direct ownership of 159,248 shares.
- The transactions were conducted under a Rule 10b5-1 trading plan adopted on June 3, 2025.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted through a pre-arranged plan and does not reflect a discretionary decision based on current company performance.
Positives
- The sale was executed via a pre-planned Rule 10b5-1 trading plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.
Negatives
- The transaction represents a reduction in the direct equity stake held by the company's Chief Financial Officer.
Risks
- None identified; this is a routine disclosure of executive equity transactions.
Future Outlook
No forward-looking guidance or operational outlook provided in this filing.
Industry Context
StockSavvy.ai notes that executive stock sales under Rule 10b5-1 plans are common in the pharmaceutical industry and generally do not signal a change in corporate strategy or financial health.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate officers at large-cap pharmaceutical companies like Pfizer, Merck, and Eli Lilly to manage personal equity holdings.
Stakeholder Impact
- Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the executive's total holdings.
Key Dates
| Date | Description |
|---|---|
| 06/03/2025 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 04/01/2026 | Date of the reported stock sale transactions. |
| 04/02/2026 | Date the Form 4 was signed and filed. |
Keywords
Bristol-Myers Squibb, BMY, Insider Trading, Form 4, Executive Compensation, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.